Published in Trends Genet on August 06, 2007
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One (2010) 8.10
Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16
Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget (2012) 1.40
Epigenetics in acute myeloid leukemia. Semin Oncol (2008) 1.16
LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Mol Cell (2012) 1.00
Architectural epigenetics: mitotic retention of mammalian transcriptional regulatory information. Mol Cell Biol (2010) 0.97
TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One (2012) 0.96
DNA methylation patterns in bladder cancer and washing cell sediments: a perspective for tumor recurrence detection. BMC Cancer (2008) 0.94
BTECH: a platform to integrate genomic, transcriptomic and epigenomic alterations in brain tumors. Neuroinformatics (2011) 0.81
A time for atlases and atlases for time. Front Syst Neurosci (2010) 0.77
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet (2011) 3.73
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol (2007) 2.64
Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet (2005) 2.63
Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw (2013) 2.56
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 2.50
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
Non-small cell lung cancer. J Natl Compr Canc Netw (2012) 2.40
Restriction landmark genome scanning. Methods (2002) 2.20
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet (2003) 2.18
Lung cancer epigenetics and genetics. Int J Cancer (2008) 2.08
Regulation of DNA methylation of Rasgrf1. Nat Genet (2001) 2.06
Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol (2003) 2.04
Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol (2006) 2.02
SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A (2003) 2.01
Lung cancer screening. J Natl Compr Canc Netw (2012) 2.00
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res (2013) 1.86
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci U S A (2006) 1.75
Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst (2006) 1.72
Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw (2014) 1.71
Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res (2005) 1.69
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome. Hum Mol Genet (2007) 1.68
Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene (2003) 1.64
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents (2003) 1.58
MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem Biophys Res Commun (2009) 1.58
20q11.1 amplification in giant-cell tumor of bone: Array CGH, FISH, and association with outcome. Genes Chromosomes Cancer (2006) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
5-aza-2'-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem (2004) 1.54
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res (2004) 1.52
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. Cancer Res (2008) 1.49
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res (2006) 1.49
HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A (2002) 1.43
Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res (2008) 1.43
Preoperative bevacizumab in combination with paclitaxel and carboplatin in surgically resectable non-small cell lung cancer. Ann Thorac Surg (2011) 1.42
Tissue specific DNA methylation of CpG islands in normal human adult somatic tissues distinguishes neural from non-neural tissues. Epigenetics (2010) 1.41
DNA motifs associated with aberrant CpG island methylation. Genomics (2006) 1.40
TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol (2005) 1.39
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2009) 1.39
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol (2006) 1.37
Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma. J Biol Chem (2002) 1.35
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol (2013) 1.34
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34
miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer Res (2012) 1.33
Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene (2002) 1.32
CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS Genet (2007) 1.28
Toward a human epigenome. Nat Genet (2006) 1.28
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst (2004) 1.27
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood (2009) 1.25
Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med (2013) 1.23
Pulmonary neuroendocrine/carcinoid tumors: a review article. Cancer (2009) 1.23
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene (2003) 1.23
The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene (2002) 1.22
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. Genomics (2004) 1.20
Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood (2010) 1.19
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Aging results in hypermethylation of ribosomal DNA in sperm and liver of male rats. Proc Natl Acad Sci U S A (2003) 1.19
Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res (2012) 1.18
MicroRNAs in the pathogenesis of Lung Cancer. J Thorac Oncol (2009) 1.17
Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med (Berl) (2006) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array. BMC Genomics (2008) 1.15
Tagmentation-based whole-genome bisulfite sequencing. Nat Protoc (2013) 1.14
Cancer chemoprevention by targeting the epigenome. Curr Drug Targets (2011) 1.13
A novel classification of lung cancer into molecular subtypes. PLoS One (2012) 1.13
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood (2008) 1.12
Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood (2011) 1.12
Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov (2013) 1.11
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest (2012) 1.11
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10
Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB. PLoS Genet (2013) 1.08
HOXB13, a target of DNMT3B, is methylated at an upstream CpG island, and functions as a tumor suppressor in primary colorectal tumors. PLoS One (2010) 1.08
Structural characterization of Rasgrf1 and a novel linked imprinted locus. Gene (2002) 1.07
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol (2002) 1.07
Restriction landmark genomic scanning (RLGS) spot identification by second generation virtual RLGS in multiple genomes with multiple enzyme combinations. BMC Genomics (2007) 1.07
Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs (2011) 1.07
Bone morphogenetic protein 3B silencing in non-small-cell lung cancer. Oncogene (2004) 1.06
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 1.06
A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. Epigenetics (2012) 1.05
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. Exp Cell Res (2006) 1.04
Alterations of DNA methylation in hematologic malignancies. Cancer Lett (2002) 1.04